---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-041784"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:40:51.203793+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia doses first patient in higher-dose Phase 1 study of DA-1726 for obesity

## Summary
- Part 3 of Phase 1 evaluates one-step (16→48 mg) and two-step (16→32→64 mg) titration over 16 weeks in 40 obese adults.
- Previously reported ~9% weight loss at 48 mg dose with favorable tolerability; glycemic and liver benefit signals.
- Data from Part 3 expected in Q4 2026; primary endpoints are safety and tolerability.
- DA-1726 is a dual GLP-1/glucagon (OXM) analog; company aims for differentiated efficacy and simpler titration.

## SEC filing metadata
- accession: 0001104659-26-041784
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/0001104659-26-041784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-041784
- JSON: https://secwatch.observer/filing/0001104659-26-041784.json
- Plain text: https://secwatch.observer/filing/0001104659-26-041784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.